New approaches in the management of insomnia: Weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists

Neuropsychiatric Disease and Treatment

Volumn 5, Issue 1, 2009, Pages 341-354

  Hardeland, Rüdiger ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Agomelatine; Hypnotics; Melatonin; Prolonged release; Ramelteon; Tasimelteon

Indexed keywords

6 CHLOROMELATONIN; AGOMELATINE; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA METHYL 6 CHLOROMELATONIN; BMS 214778; LY 156735; MA 1; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN DERIVATIVE; PLACEBO; RAMELTEON; TASIMELTEON; UNCLASSIFIED DRUG; VEC 162;

AREA UNDER THE CURVE; AUTOIMMUNE DISEASE; CIRCADIAN RHYTHM SLEEP DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; CONCENTRATION LOSS; CONTINUOUS INFUSION; CONTROLLED RELEASE FORMULATION; DIGESTIVE SYSTEM FUNCTION DISORDER; DIZZINESS; DOSE RESPONSE; DRIVING ABILITY; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG ELIMINATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TOLERANCE; EVENING DOSAGE; HALF LIFE TIME; HUMAN; INSOMNIA; JET LAG; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; MEMORY DISORDER; MOOD CHANGE; MORNING DOSAGE; NAUSEA; NONHUMAN; PAIN; PARKINSONISM; PSYCHOMOTOR DISORDER; RECEPTOR AFFINITY; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SLOW RELEASE FORMULATION; SMITH MAGENIS SYNDROME; SUPRACHIASMATIC NUCLEUS; SUSTAINED RELEASE FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 70449704975     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/ndt.s4234     Document Type: Review

References (133)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition (DSM-IV), text revision. Washington, DC: American Psychiatric Association; 2000.
2. Drake CL, Roehrs T, Roth T. Insomnia causes, consequences, and therapeutics: an overview. Depress Anxiety. 2003;18:163-176. (Pubitemid 38056063)
3. National Institutes of Health. NIH statement regarding the treatment of insomnia. State of the Science Conference Statement: Manifestations and management of chronic insomnia ind adults. Sleep. 2005;28:1049-1057.
4. Singer C, Tractenberg RE, Kaye J, Schafer K, Gamst A, Grundman M, et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep. 2003;26:893-901. (Pubitemid 39610638)
5. Skene DJ, Swaab DF. Melatonin rhythmicity: effect of age and Alzheimer's disease. Exp Gerontol. 2003;38:199-206. (Pubitemid 36110514)
6. Srinivasan V, Pandi-Perumal SR, Cardinali DP, Poeggeler B, Hardeland R. Melatonin in Alzheimer's disease and other neurodegenerative disorders. Behav Brain Funct. 2006;2:15. (Pubitemid 43994747)
7. Wu YH, Swaab DF. Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease. Sleep Med. 2007;8:623-636.
8. Lockley SW, Skene DJ, Butler LJ, Arendt J. Sleep and activity rhythms are related to circadian phase in the blind. Sleep. 1999;22:616-623. (Pubitemid 29379118)
9. Ebisawa T. Circadian rhythms in the CNS and peripheral clock disorders: human sleep disorders and clock genes. J Pharmacol Sci. 2007;103:150-154. (Pubitemid 46294645)
10. Okawa M, Uchiyama M. Circadian rhythm sleep disorders and entrainment pathology in delayed sleep phase and non-24-h sleep-wake syndrome. Sleep Med Rev. 2007;11:485-496. (Pubitemid 350087715)
11. Skene DJ, Lockley SW, Arendt J. Use of melatonin in the treatment of phase shift and sleep disorders. Adv Exp Med Biol. 1999;467:79-84.
12. Kamei Y, Hayakawa T, Urata J, Uchiyama M, Shibui K, Kim K, et al. Melatonin treatment for circadian rhythm sleep disorders. Psychiatry Clin Neurosci. 2000;54:391-392. (Pubitemid 30431868)
13. Zisapel N. Circadian sleep disorders: pathophysiology and potential approaches to management. CNS Drugs. 2001;15:311-328. (Pubitemid 32337053)
14. Szeinberg A, Borodkin A, Dagan Y. Melatonin treatment in adolescents with delayed sleep phase syndrome. Clin Pediatr (Phila). 2006;45:809-818. (Pubitemid 44570028)
15. Liu C, Weaver DR, Jin X, Shearman LP, Pieschl RL, Gribkoff VK, et al. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic clock. Neuron. 1997;19:91-102. (Pubitemid 27332996)
16. von Gall C, Stehle JH, Weaver DR. Mammalian melatonin receptors: molecular biology and signal transduction. Cell Tissue Res. 2002;309:151-162. (Pubitemid 34744037)
17. 1b melatonin receptor. Mol Cell Biol. 2003;23:1054-1060.
18. 2 melatonin receptors in mammals. Endocrine. 2005;27:101-110.
19. Hardeland R. Melatonin: Signaling mechanisms of a pleiotropic agent. BioFactors. 2009;35:183-192.
20. Pandi-Perumal SR, Srinivasan V, Poeggeler B, Hardeland R, Cardinali DP. Drug insight: the use of melatonergic agonists for the treatment of insomnia - focus on ramelteon. Nat Clin Pract Neurol. 2007;3:221-228. (Pubitemid 46605272)
21. Hardeland R, Poeggeler B, Srinivasan V, Trakht I, Pandi-Perumal SR, Cardinali DP. Melatonergic drugs in clinical practice. Arzneimittelforschung. 2008;58:1-10.
22. Srinivasan V, Pandi-Perumal SR, Trahkt I, Spence DW, Poeggeler B, Hardeland R, et al. Melatonin and melatonergic drugs on sleep: possible mechanisms of action. Int J Neurosci. 2009;119:821-846.
23. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature. 2005;437:1257-1263. (Pubitemid 41568665)
24. Fuller PM, Gooley JJ, Saper CB. Neurobiology of sleep-wake cycle, sleep architecture, circadian regulation and regulatory feed back. J Biol Rhythms. 2006;21:482-493.
25. Reppert SM, Godson C, Mahle CD, Weaver DR, Slaugenhaupt SA, Gusella JF. Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci U S A. 1995;92:8734-8738.
26. Mazzucchelli C, Pannacci M, Nonno R, Lucini V, Fraschini F, Stankov BM. The melatonin receptor in the human brain: cloning experiments and distribution studies. Brain Res Mol Brain Res. 1996;39:117-126. (Pubitemid 26179152)
27. 1 gene expression. J Pineal Res. 2002;33:218-224.
28. Ambriz-Tututi M, Rocha-González HI, Cruz SL, Granados-Soto V. Melatonin: A hormone that modulates pain. Life Sci. 2009;84:489-498.
29. Dijk DJ, Roth C, Landolt HP, Werth E, Aeppli M, Achermann P, et al. Melatonin effect on daytime sleep in men: suppression of EEG low frequency activity and enhancement of spindle frequency activity. Neurosci Lett. 1995;201:13-16.
30. Jan JE, Reiter RJ, Wasdell MB, Bax M. The role of the thalamus in sleep, pineal melatonin production, and circadian rhythm sleep disorders. J Pineal Res. 2009;46:1-7.
31. De Gennaro L, Ferrara M. Sleep spindles. An overview. Sleep Med Rev. 2003;7:423-440.
32. Morin LP, Allen CN. The circadian visual system, 2005. Brain Res Rev. 2006;51:1-60.
33. Jan JE, Wasdell MB, Reiter RJ, Weiss MD, Johnson KP, Ivanenko A, et al. Melatonin therapy of pediatric sleep disorders: recent advances, why it works, who are the candidates and how to treat. Curr Pediatr Rev. 2007;3:214-224. (Pubitemid 47335313)
34. Cajochen C, Münch M, Knoblauch V, Blatter K, Wirz-Justice A. Age-related changes in the circadian and homeostatic regulation of human sleep. Chronobiol Int. 2006;23:461-474. (Pubitemid 43739057)
35. Gorfine T, Zisapel N. Late evening brain activation patterns and their relation to the internal biological time, melatonin, and homeostatic sleep debt. Hum Brain Mapp. 2009;30:541-552.
36. Dijk DJ, von Schantz M. Timing and consolidation of human sleep, wakefulness, and performance by a symphony of oscillators. J Biol Rhythms. 2005;20:279-290.
37. Cajochen C, Kräuchi K, Wirz-Justice A. Role of melatonin in the regulation of human circadian rhythms and sleep. J Neuroendocrinol. 2003;15:432-437. (Pubitemid 36395244)
38. Hardeland R. Antioxidative protection by melatonin - Multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine. 2005;27:119-130. (Pubitemid 41558444)
39. Lu J, Sherman D, Devor M, Saper CB. A putative flip-flop switch for control of REM sleep. Nature. 2006;441:589-594. (Pubitemid 43927285)
40. Fuller PM, Saper CB, Lu J. The pontine REM switch: past and present. J Physiol. 2007;584:735-741. (Pubitemid 350031919)
41. Kunz D, Mahlberg R, Müller C, Tilmann A, Bes F. Melatonin in patients with reduced REM sleep duration: two randomized controlled trials. J Clin Endocrinol Metab. 2004;89:128-134. (Pubitemid 38183871)
42. Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev. 2005;9:11-24.
43. Hardeland R, Poeggeler B. Actions of melatonin, its structural and functional analogs in the central nervous system and the significance of metabolism. Cent Nerv Syst Agents Med Chem. 1007;7:289-303.
44. Hardeland R, Poeggeler B. Melatonin beyond its classical functions. Open Physiol J. 2008;1:1-23.
45. Hardeland R. Melatonin, hormone of darkness and more - occurrence, control mechanisms, actions and bioactive metabolites. Cell Mol Life Sci. 2008;65:2001-2018.
46. 2 receptor agonist. Neuropharmacology. 2005;48:301-310.
47. Poeggeler B, Hardeland R. Melatoninerge Chronobiotika: Wirkungen und Probleme. In: Hardeland R, editor. Facetten der Chronobiologie. Abh Leibniz-Soz, Vol 23. Berlin: Trafo; 2008. p. 71-87.
48. Ma X, Idle JR, Krausz KW, Gonzalez FJ. Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005;33:489-494. (Pubitemid 40393190)
49. Pandi-Perumal SR, Srinivasan V, Maestroni GJM, Cardinali DP, Poeggeler B, Hardeland R. Melatonin - Nature's most versatile biological signal? FEBS J. 2006;273:2813-2838. (Pubitemid 43910039)
50. Feldstein A, Chang FH, Kucharski JM. Tryptophol, 5-hydroxytryptophol and 5-methoxytryptophol induced sleep in mice. Life Sci. 1970;9:323-329.
51. EMEA. Assessment report for Circadin. 2007;52 p. Available from: http.//www.emea.europe.eu/humandocs/PDFs/EPAR/Circadin/H-695-eu6.pdf.
52. Huether G, Messner M, Rodenbeck A, Hardeland R. Effect of continuous melatonin infusions on steady-state plasma melatonin levels in rats under near physiological conditions. J Pineal Res. 1998;24:146-151. (Pubitemid 28156599)
53. Hajak G, Huether G, Blanke J, Blömer M, Freyer C, Poeggeler B, et al. The influence of intravenous L-tryptophan on plasma melatonin and sleep in men. Pharmacopsychiatry. 1991;24:17-20.
54. Bubenik GA. Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci. 2002;47:2336-2348. (Pubitemid 35205309)
55. Hardeland R, Pandi-Perumal SR. Melatonin, a potent agent in antioxidative defense: Actions as a natural food constituent, gastrointestinal factor, drug and prodrug. Nutr Metab (Lond). 2, 2005; article no 22 [DOI 10.1186/1743-7075-2- 22]. (Pubitemid 41451115)
56. Poeggeler B, Cornélissen G, Huether G, Hardeland R, Józsa R, Zeman M, et al. Chronomics affirm extending scope of lead in phase of duodenal vs pineal circadian melatonin rhythms. Biomed Pharmacother. 2005;59:S220-S224. (Pubitemid 41586173)
57. Tan DX, Manchester LC, Reiter RJ, Qi W, Hanes MA, Farley NJ. High physiological levels of melatonin in the bile of mammals. Life Sci. 1999;65:2523-2529.
58. Messner M, Huether G, Lorf T, Ramadori G, Schwörer H. Presence of melatonin in the human hepatobiliary-gastrointestinal tract. Life Sci. 2001;69:543-551. (Pubitemid 32601981)
59. Huether G. Melatonin synthesis in the gastrointestinal tract and the impact of nutritional factors on circulating melatonin. Ann N Y Acad Sci. 1994;719:146-158. (Pubitemid 24199972)
60. Lee BJ, Ryu SG, Choi HG, Kim CK, Parrott KA, Ayres JW, et al. Batch variation and pharmacokinetics of oral sustained release melatonin-loaded sugar spheres in human subjects. Arch Pharm Res. 1997;20:555-559.
61. Priano L, Esposti D, Esposti R, Castagna G, De Medici C, Fraschini F, et al. Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery systems. J Nanosci Nanotechnol. 2007;7:3596-3601.
62. Mulchahey JJ, Goldwater DR, Zemlan FP. A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog β-methyl-6-chloromelatonin. Life Sci. 2004;75:1843-1856.
63. Zemlan FP, Mulchahey JJ, Scharf MB, Mayleben DW, Rosenberg R, Lankford A. The efficacy and safety of the melatonin agonist β-methyl-6- chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. J Clin Psychiatry. 2005;66:384-390. (Pubitemid 40476763)
64. EMEA. Questions and answers on recommendation for the refusal of the marketing authorisation for ramelteon. Press Release, May 30, 2008. http://www.emea.europa.eu/pdfs/human/opinion/Ramelteon-26821608en.pdf.
65. EMEA. Takeda withdraws its marketing authorisation application for Ramelteon. Press Release, September 25, 2008. http://www.emea.europa.eu/ humandocs/PDFs/EPAR/ramelteon/50471608en.pdf.
66. Miyamoto M, Nishikawa H, Ohta H, Uchikawa O, Ohkawa O, Ohkawa S. Behavioural pharmacology of TAK-375 in small animals. Ann Neurol. 2003;54:S46.
67. McGechan A, Wellington K. Ramelteon. CNS Drugs. 2005;19:1057-1065.
68. 2 melatonin receptor agonist indicated for the treatment of insomnia. J Clin Pharmacol. 2006;46:140-148.
69. Rajaratnam SM, Polymeropoulos MH, Fisher DM, Roth T, Scott C, Birznieks G, et al. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet. 2009;373:482-491.
70. Klerman EB Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Web Appendix to online prepublication of ref. 53. 2008;www.thelancet.com.
71. Vachharajani NN, Yeleswaram K, Boulton DW. Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist. J Pharm Sci. 2003;92:760-772. (Pubitemid 36396993)
72. IDdb Author. Associated Professional Sleep Societies - 20 Annual Meeting (Part I), Hypnotic and Wake-promoting Drugs, Salt Lake City, UT, USA. IDdb Meeting Report; 2006, June 17-22.
73. Zhu M, Mitroka J, Shaw AA, Luke GM, Vachharajani N, Kripalani KJ. Identification of in vitro and in vivo metabolites of BMS-214778 in monkeys by ion trap LC/MS and LC/NMR. Drug Metab Rev. 2000;32 Suppl 2:260.
74. 2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003;306:954-964.
75. Servier Pharma. Valdoxan® (agomelatine), a novel antidepressant, receives European marketing authorization. Servier Press Release. 2009;http://www.agomelatine.org/2009-valdoxan.html.
76. Carr R, Wasdell MB, Hamilton D, Weiss MD, Freeman RD, Tai J, et al. Long-term effectiveness outcome of melatonin therapy in children with treatment-resistant circadian rhythm sleep disorders. J Pineal Res. 2007;43:351-359. (Pubitemid 47512266)
77. Wade AG, Ford I, Crawford G, McMahon AD, Nir T, Laudon M, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin. 2007;23:2597-2605. (Pubitemid 350033462)
78. Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res. 2007;16:372-380. (Pubitemid 350151283)
79. Haimov I, Lavie P, Laudon M, Herer P, Vigder C, Zisapel N. Melatonin replacement therapy of elderly insomniacs. Sleep. 1995;18:598-603.
80. Suhner A, Schlagenhauf P, Johnson R, Tschopp A, Steffen R. Comparative study to determine the optimal melatonin dosage form for the alleviation of jet lag. Chronobiol Int. 1998;15:655-666. (Pubitemid 28544205)
81. Herxheimer A, Petrie KKJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev. 2002;(2): article no. CD001520. DOI: 10.1002/14651858.CD001520.
82. Paul MA, Gray G, Sardana TM, Pigeau RA. Melatonin and zopiclone as facilitators of early circadian sleep in operational air transport crews. Aviat Space Environ Med. 2004;75:439-443. (Pubitemid 38542338)
83. Sharkey KM, Fogg LF, Eastman CI. Effects of melatonin administration on daytime sleep after simulated night shift work. J Sleep Res. 2001;10:181-192.
84. Crowley SJ, Lee C, Tseng CY, Fogg LF, Eastman CI. Combinations of bright light, scheduled dark, sunglasses, and melatonin to facilitate circadian entrainment to night shift work. J Biol Rhythms. 2003;18:513-523. (Pubitemid 37463301)
85. Jan JE, Hamilton D, Seward N, Fast DK, Freeman RD, Laudon M. Clinical trials of controlled-release melatonin in children with sleep-wake cycle disorders. J Pineal Res. 2000;29:34-39. (Pubitemid 30449699)
86. Wasdell MB, Jan JE, Bomben MM, Freeman RD, Rietveld WJ, Tai J, et al. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res. 2008;44:57-64. (Pubitemid 350231110)
87. Potocki L, Glaze D, Tan DX, Park SS, Kashork CD, Shaffer LG, et al. Circadian rhythm abnormalities of melatonin in Smith-Magenis syndrome. J Med Genet. 2000;37:428-433. (Pubitemid 30386734)
88. De Leersnyder H. Inverted rhythm of melatonin secretion in Smith-Magenis syndrome: from symptoms to treatment. Trends Endocrinol Metab. 2006;17:291-298. (Pubitemid 44287474)
89. De Leersnyder H, Claustrat B, Munnich A, Verloes A. Circadian rhythm disorder in a rare disease: Smith-Magenis syndrome. Mol Cell Endocrinol. 2006;252:88-91. (Pubitemid 43914111)
90. Carpizo R, Martínez A, Mediavilla D, González M, Abad A, Sánchez-Barceló EJ. Smith-Magenis syndrome: a case report of improved sleep after treatment with β1-adrenergic antagonists and melatonin. J Pediatr. 2006;149:409-411. (Pubitemid 44308427)
91. Jan JE, Espezel H, Appleton RE. The treatment of sleep disorders with melatonin. Dev Med Child Neurol. 1994;36:97-107.
92. McArthur AJ, Budden SS. Sleep dysfunction in Rett syndrome: a trial of exogenous melatonin treatment. Dev Med Child Neurol. 1998;40:186-192.
93. Ishizaki A, Sugama M, Takeuchi N. [Usefulness of melatonin for developmental sleep and emotional/behavior disorders-studies of melatonin trial on 50 patients with developmental disorders.] [in Japanese]. No To Hattatsu. 1999;31:428-437.
94. Andersen IM, Kaczmarska J, McGrew SG, Malow BA. Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol. 2008;23:482-485. (Pubitemid 351566859)
95. Giannotti F, Cortesi F, Cerquiglini A, Bernabei P. An open-label study of controlled-release melatonin in treatment of sleep disorders in children with autism. J Autism Dev Disord. 2006;36:741-752. (Pubitemid 44284978)
96. Dolberg OT, Hirschmann S, Grunhaus L. Melatonin for the treatment of sleep disturbances in major depressive disorder. Am J Psychiatry. 1998;155:1119-1121. (Pubitemid 28357744)
97. Dalton EJ, Rotondi D, Levitan RD, Kennedy SH, Brown GM. Use of slow-release melatonin in treatment-resistant depression. J Psychiatry Neurosci. 2000;25:48-52. (Pubitemid 30143328)
98. Shilo L, Dagan Y, Smorjik Y, Weinberg U, Dolev S, Komptel B, et al. Effect of melatonin on sleep quality of COPD intensive care patients: a pilot study. Chronobiol Int. 2000;17:71-76. (Pubitemid 30078522)
99. Shamir E, Laudon M, Barak Y, Anis Y, Rotenberg V, Elizur A, et al. Melatonin improves sleep quality of patients with chronic schizophrenia. J Clin Psychiatry. 2000;61:373-377. (Pubitemid 30345940)
100. Shamir E, Rotenberg VS, Laudon M, Zisapel N, Elizur A. First-night effect of melatonin treatment in patients with chronic schizophrenia. J Clin Psychopharmacol. 2000;20:691-694. (Pubitemid 30953811)
101. Serfaty M, Kennell-Webb S, Warner J, Blizard R, Raven P. Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. Int J Geriatr Psychiatry. 2002;17:1120-1127. (Pubitemid 35469219)
102. Borja NL, Daniel KL. Ramelteon for the treatment of insomnia. Clin Ther. 2006;28:1540-1555.
103. Neubauer DN. A review of ramelteon in the treatment of sleep disorders. Neuropsychiatr Dis Treat. 2008;4:69-79.
104. Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med. 2006;7:312-318. (Pubitemid 43792892)
105. Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med. 2006;7:17-24. (Pubitemid 43033540)
106. Roth T, Seiden D, Wang-Weigand S, Zhang J. A 2-night, 3-period, crossover study on ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin. 2007;23:1005-1014. (Pubitemid 46799582)
107. Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med. 2007;3:495-504. (Pubitemid 47378253)
108. Kryger M, Wang-Weigand S, Roth T. Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea. Sleep Breath. 2007;11:159-164. (Pubitemid 47307844)
109. Otmani S, Demazières A, Staner C, Jacob N, Nir T, Zisapel N, et al. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum Psychopharmacol. 2008;23:693-705.
110. Garfinkel D, Zisapel N, Wainstein J, Laudon M. Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach. Arch Intern Med. 1999;159:2456-2460. (Pubitemid 29526774)
111. Weishaupt JH, Bartels C, Pölking E, Dietrich J, Rohde G, Poeggeler B, et al. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res. 2006;41:313-323. (Pubitemid 44498217)
112. Silman RE. Melatonin: a contraceptive for the nineties. Eur J Obstet Gynecol Reprod Biol. 1993;49:3-9.
113. García-Patterson A, Puig-Domingo M, Webb SM. Thirty years of human pineal research: do we know its clinical relevance? J Pineal Res. 1996;20:1-6. (Pubitemid 126732259)
114. Bubenik GA, Blask DE, Brown GM, Maestroni GJ, Pang SF, Reiter RJ, et al. Prospects of the clinical utilization of melatonin. Biol Signals Recept. 1998;7:195-219.
115. Silman R. Melatonin and the human gonadotrophin-releasing hormone pulse generator. J Endocrinol. 1991;128:7-11.
116. Waldhauser F, Boepple PA, Schemper M, Mansfield MJ, Crowley WF Jr. Serum melatonin in central precocious puberty is lower than in age-matched prepubertal children. J Clin Endocrinol Metab. 1991;73:793-796. (Pubitemid 21921940)
117. Walker AB, English J, Arendt J, MacFarlane IA. Hypogonadotrophic hypogonadism and primary amenorrhoea associated with increased melatonin secretion from a cystic pineal lesion. Clin Endocrinol (Oxf). 1996;45:353-356. (Pubitemid 26306704)
118. Luboshitzky R, Herer P, Shen-Orr Z. Urinary 6-sulfatoxymelatonin excretion in hyperandrogenic women: the effect of cyproterone acetate-ethinyl estradiol treatment. Exp Clin Endocrinol Diabetes. 2004;112:102-107. (Pubitemid 38435709)
119. Rohr UD, Herold J. Melatonin deficiencies in women. Maturitas. 2002;41 Suppl 1:S85-S104.
120. Luboshitzky R, Levi M, Shen-Orr Z, Blumenfeld Z, Herer P, Lavie P. Long-term melatonin administration does not alter pituitary-gonadal hormone secretion in normal men. Hum Reprod. 2000;15:60-65. (Pubitemid 30035100)
121. Luboshitzky R, Shen-Orr Z, Nave R, Lavi S, Lavie P. Melatonin administration alters semen quality in healthy men. J Androl. 2002;23:572-578. (Pubitemid 34655092)
122. Palm L, Blennow G, Wetterberg L. Long-term melatonin treatment in blind children and young adults with circadian sleep-wake disturbances. Dev Med Child Neurol. 1997;39:319-325. (Pubitemid 27271709)
123. Jan JE, Freeman RD, Fast DK. Melatonin treatment of sleep-wake cycle disorders in children and adolescents. Dev Med Child Neurol. 1999;41:491-500. (Pubitemid 29322492)
124. Dodge NN, Wilson GA. Melatonin for treatment of sleep disorders in children with developmental disabilities. J Child Neurol. 2001;16:581-584. (Pubitemid 32798881)
125. Takeda Pharmaceuticals America, Inc. Rozerem™ (ramelteon) tablets. 05-1118;L-RAM-00010. 2005.
126. Willis GL. Parkinson's disease as a neuroendocrine disorder of circadian function: dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process. Rev Neurosci. 2008;19:245-316.
127. Willis GL. The role of ML-23 and other melatonin analogues in the treatment and management of Parkinson's disease. Drug News Perspect. 2005;18:437-444.
128. Osadchuk AM, Osadchuk MA, Kvetno IM. [Irritated bowel syndrome: clinico-morphological types.] [Article in Russian] Klin Med (Mosk). 2007;85:46-50.
129. Hardeland R, Pandi-Perumal SR, Cardinali DP. Molecules in focus - Melatonin. Int J Biochem Cell Biol. 2006;38:313-316.
130. Fava M, Asnis G, Shrivastava R, Lydiard RB, Bastani B, Sheehan D, et al. Improved insomnia symptoms and daily functioning in patients with comorbid major depressive disorder and insomnia following zolpidem extended-release 12.5 mg and escitalopram co-treatment. Sleep. 2008;31:A324.
131. Kryger M, Roth T, Wang-Weigand S, Zhang J. The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease. Sleep Breath. 2009;13:79-84.
132. Roth T. Hypnotic use for insomnia management in chronic obstructive pulmonary disease. Sleep Med. 2009;10:19-25.
133. Nunes DM, Mota RM, Machado MO, Pereira ED, de Bruin VM, de Bruin PF. Effect of melatonin administration on subjective sleep quality in chronic obstructive pulmonary disease. Braz J Med Biol Res. 2008;41:926-931.